| Aducanumab offers patients and caregivers … . | |
|---|---|
| … hope. | • ‘Although it may not help, at least aducanumab has given us a glimmer of hope in fighting this terrible disease.’ (Family member/caregiver of person living with Alzheimer’s disease) • ‘Even though there are potential serious side effects, the drug offers hope for patients who otherwise will experience the progression of Alzheimer’s disease. As the care giver for my [PHI Redacted] who had Alzheimer’s disease, I can say that without a doubt that the potential for the medication to stop the ravages of Alzheimer’s disease far outweighs any possibility of side effects.’ (Family member/caregiver of person living with Alzheimer’s disease) • ‘As the field makes its way into the devastating disease of AD, it is my sincere wish that those suffering are provided the hope to preserve their precious minds that they yearn for. There has never been more hope for AD treatment than there is now. Why does CMS want to strip patients of that?’ (Clinician or other health care worker) |
| … false hope. | • ‘Without any evidence that this drug actually works, it is snake oil, and taxing to patients who cling to hope but also need to spend their remaining time wisely.’ (Clinician or other health care worker) • ‘People with Alzheimer’s aren’t marks—they are human beings who deserve to be treated with dignity and respect—not sold false hope.’ (Family member/caregiver of person living with Alzheimer’s disease; Self-identified member of the general public/taxpayer) • ‘Their profits should not be at the expense of the rest of us, certainly not those on Medicare and with Alzheimer’s, whose desperation is being exploited.’ (Not specified) |
| … a choice. | • ‘One concern cited about Aduhelm is potential side effects: headache (most common), diarrhea and confusion or (less common) falls and brain swelling/bleeding. People living with Alzheimer’s should have the right to weigh these risks in consultation with their physicians. Since the disease leads to certain death, most would likely consider potential side effects worth the risk.’ (Other) • `It is hard for me to understand why this drug would be kept from people suffering from this cruel disease. All drugs have side effects. These are trade off’s that people deserve the opportunity to make informed decisions about.' (Family member/caregiver of person living with Alzheimer’s disease) • ‘The draft memorandum limits the autonomy of those living with dementia or Alzheimer’s disease to make informed decisions about their own care and whether they themselves would be willing to assume any risk in order to potentially benefit from receiving treatment.’ (Alzheimer’s patient advocacy organization) |
| Aducanumab offers patients and caregivers … . | |
|---|---|
| … hope. | • ‘Although it may not help, at least aducanumab has given us a glimmer of hope in fighting this terrible disease.’ (Family member/caregiver of person living with Alzheimer’s disease) • ‘Even though there are potential serious side effects, the drug offers hope for patients who otherwise will experience the progression of Alzheimer’s disease. As the care giver for my [PHI Redacted] who had Alzheimer’s disease, I can say that without a doubt that the potential for the medication to stop the ravages of Alzheimer’s disease far outweighs any possibility of side effects.’ (Family member/caregiver of person living with Alzheimer’s disease) • ‘As the field makes its way into the devastating disease of AD, it is my sincere wish that those suffering are provided the hope to preserve their precious minds that they yearn for. There has never been more hope for AD treatment than there is now. Why does CMS want to strip patients of that?’ (Clinician or other health care worker) |
| … false hope. | • ‘Without any evidence that this drug actually works, it is snake oil, and taxing to patients who cling to hope but also need to spend their remaining time wisely.’ (Clinician or other health care worker) • ‘People with Alzheimer’s aren’t marks—they are human beings who deserve to be treated with dignity and respect—not sold false hope.’ (Family member/caregiver of person living with Alzheimer’s disease; Self-identified member of the general public/taxpayer) • ‘Their profits should not be at the expense of the rest of us, certainly not those on Medicare and with Alzheimer’s, whose desperation is being exploited.’ (Not specified) |
| … a choice. | • ‘One concern cited about Aduhelm is potential side effects: headache (most common), diarrhea and confusion or (less common) falls and brain swelling/bleeding. People living with Alzheimer’s should have the right to weigh these risks in consultation with their physicians. Since the disease leads to certain death, most would likely consider potential side effects worth the risk.’ (Other) • `It is hard for me to understand why this drug would be kept from people suffering from this cruel disease. All drugs have side effects. These are trade off’s that people deserve the opportunity to make informed decisions about.' (Family member/caregiver of person living with Alzheimer’s disease) • ‘The draft memorandum limits the autonomy of those living with dementia or Alzheimer’s disease to make informed decisions about their own care and whether they themselves would be willing to assume any risk in order to potentially benefit from receiving treatment.’ (Alzheimer’s patient advocacy organization) |
| Aducanumab offers patients and caregivers … . | |
|---|---|
| … hope. | • ‘Although it may not help, at least aducanumab has given us a glimmer of hope in fighting this terrible disease.’ (Family member/caregiver of person living with Alzheimer’s disease) • ‘Even though there are potential serious side effects, the drug offers hope for patients who otherwise will experience the progression of Alzheimer’s disease. As the care giver for my [PHI Redacted] who had Alzheimer’s disease, I can say that without a doubt that the potential for the medication to stop the ravages of Alzheimer’s disease far outweighs any possibility of side effects.’ (Family member/caregiver of person living with Alzheimer’s disease) • ‘As the field makes its way into the devastating disease of AD, it is my sincere wish that those suffering are provided the hope to preserve their precious minds that they yearn for. There has never been more hope for AD treatment than there is now. Why does CMS want to strip patients of that?’ (Clinician or other health care worker) |
| … false hope. | • ‘Without any evidence that this drug actually works, it is snake oil, and taxing to patients who cling to hope but also need to spend their remaining time wisely.’ (Clinician or other health care worker) • ‘People with Alzheimer’s aren’t marks—they are human beings who deserve to be treated with dignity and respect—not sold false hope.’ (Family member/caregiver of person living with Alzheimer’s disease; Self-identified member of the general public/taxpayer) • ‘Their profits should not be at the expense of the rest of us, certainly not those on Medicare and with Alzheimer’s, whose desperation is being exploited.’ (Not specified) |
| … a choice. | • ‘One concern cited about Aduhelm is potential side effects: headache (most common), diarrhea and confusion or (less common) falls and brain swelling/bleeding. People living with Alzheimer’s should have the right to weigh these risks in consultation with their physicians. Since the disease leads to certain death, most would likely consider potential side effects worth the risk.’ (Other) • `It is hard for me to understand why this drug would be kept from people suffering from this cruel disease. All drugs have side effects. These are trade off’s that people deserve the opportunity to make informed decisions about.' (Family member/caregiver of person living with Alzheimer’s disease) • ‘The draft memorandum limits the autonomy of those living with dementia or Alzheimer’s disease to make informed decisions about their own care and whether they themselves would be willing to assume any risk in order to potentially benefit from receiving treatment.’ (Alzheimer’s patient advocacy organization) |
| Aducanumab offers patients and caregivers … . | |
|---|---|
| … hope. | • ‘Although it may not help, at least aducanumab has given us a glimmer of hope in fighting this terrible disease.’ (Family member/caregiver of person living with Alzheimer’s disease) • ‘Even though there are potential serious side effects, the drug offers hope for patients who otherwise will experience the progression of Alzheimer’s disease. As the care giver for my [PHI Redacted] who had Alzheimer’s disease, I can say that without a doubt that the potential for the medication to stop the ravages of Alzheimer’s disease far outweighs any possibility of side effects.’ (Family member/caregiver of person living with Alzheimer’s disease) • ‘As the field makes its way into the devastating disease of AD, it is my sincere wish that those suffering are provided the hope to preserve their precious minds that they yearn for. There has never been more hope for AD treatment than there is now. Why does CMS want to strip patients of that?’ (Clinician or other health care worker) |
| … false hope. | • ‘Without any evidence that this drug actually works, it is snake oil, and taxing to patients who cling to hope but also need to spend their remaining time wisely.’ (Clinician or other health care worker) • ‘People with Alzheimer’s aren’t marks—they are human beings who deserve to be treated with dignity and respect—not sold false hope.’ (Family member/caregiver of person living with Alzheimer’s disease; Self-identified member of the general public/taxpayer) • ‘Their profits should not be at the expense of the rest of us, certainly not those on Medicare and with Alzheimer’s, whose desperation is being exploited.’ (Not specified) |
| … a choice. | • ‘One concern cited about Aduhelm is potential side effects: headache (most common), diarrhea and confusion or (less common) falls and brain swelling/bleeding. People living with Alzheimer’s should have the right to weigh these risks in consultation with their physicians. Since the disease leads to certain death, most would likely consider potential side effects worth the risk.’ (Other) • `It is hard for me to understand why this drug would be kept from people suffering from this cruel disease. All drugs have side effects. These are trade off’s that people deserve the opportunity to make informed decisions about.' (Family member/caregiver of person living with Alzheimer’s disease) • ‘The draft memorandum limits the autonomy of those living with dementia or Alzheimer’s disease to make informed decisions about their own care and whether they themselves would be willing to assume any risk in order to potentially benefit from receiving treatment.’ (Alzheimer’s patient advocacy organization) |
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
